RxDoctor Payments Data

Michael Liou, MD

Interventional Cardiology · New York, NYNPI 1447456231

Payments from drug & device makers

$15,694in general payments, 2019–2025

Across 530 payments — averaging $29.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • AstraZeneca$1K
  • Abbott$1K
  • Boehringer Ingelheim$1K
  • Sanofi-aventis U.S. LLC$1K
  • Novartis$1K
  • plus $8K from 30 others
$550in research payments, 2019–2025

Across 1 payment — averaging $550.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Inspiremd Ltd$550

What the payments were for

  • Consulting fees$3792%
  • Speaking & faculty fees$1,0507%
  • Food & beverage$14,18590%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,694 in reported general payments places this provider in the 55th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$1,129,378
Medicare patients
456
Services billed
5,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban1,537$1,273,860
EliquisApixaban1,084$881,570
VascepaIcosapent Ethyl1,128$583,075
EntrestoSacubitril/Valsartan479$447,984
Diclofenac Epolamine377$300,248
FarxigaDapagliflozin Propanediol269$266,141
JardianceEmpagliflozin279$228,940
MultaqDronedarone Hcl121$131,687
BrilintaTicagrelor139$90,297
Diclofenac Sodium369$54,668
JanuviaSitagliptin Phosphate60$52,521
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate58$50,296
Ranolazine ErRanolazine655$42,486
Repatha SureclickEvolocumab52$39,639
Lactulose32$39,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$854$1,273,8601,537 claims
PfizerEliquis$49$881,5701,084 claims
NovartisEntresto$1,060$447,984479 claims
AstraZenecaFarxiga, Brilinta, Symbicort, Nexium$1,354$378,513494 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$1,200$248,777318 claims
Sanofi-aventis U.S. LLCMultaq$1,137$131,687121 claims
MerckJanuvia, Janumet, Verquvo$925$87,68996 claims
AbbVieCreon$14$28,12123 claims
Lilly USA, LLCTrulicity$38$23,52322 claims
Kowa Pharmaceuticals America, Inc.Livalo$175$19,46125 claims
Arbor Pharmaceuticals, Inc.Edarbi$19$15,95517 claims
Novo NordiskRybelsus$63$11,42112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →